LINC01479: A Potential Drug Target and Biomarker (G101927922)

Target Name: LINC01479

NCBI ID: G101927922

LINC01479

Other Name(s): Long intergenic non-protein coding RNA 1479 | HRAT39 | long intergenic non-protein coding RNA 1479

LINC01479: A Potential Drug Target and Biomarker

LINC01479 is a non-protein-coding RNA (ncRNA) molecule that has been identified by bioinformatics analysis as belonging to the LINC (long non-coding RNA) family. This family has been shown to play a crucial role in various biological processes, including cell development, tissue repair, and metabolism [1,2]. LINC01479 has been predicted to contain functional RNA elements, such asmiRNAs and snRNAs, which are known to interact with protein coding genes and regulate gene expression [3,4].

Drug Target Potential

The potential drug targets for LINC01479 are numerous and varied. One of the key drug targets is the inhibition of its expression, as this would lead to the downregulation of cellular processes that are critical for the survival and growth of cancer cells. LINC01479 has been shown to be involved in various cellular processes that are associated with cancer development, such as cell cycle progression, apoptosis, angiogenesis, and inflammation [5,6]. Therefore, inhibiting LINC01479 expression or function could be a promising strategy for cancer treatment.

Another potential drug target for LINC01479 is its role in cellular signaling pathways. LINC01479 has been shown to be involved in various signaling pathways, including TGF-??, NF-kB, and AP-1 signaling pathways [7,8]. Therefore, targeting LINC01479 expression or function by small molecules or antibodies could be a strategy for therapeutic intervention in diseases associated with these signaling pathways, such as cancer, neurodegenerative diseases, and autoimmune disorders.

Biomarker Potential

LINC01479 has also been identified as a potential biomarker for various diseases. The expression of LINC01479 has been shown to be affected by various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases [9,10]. For example, LINC01479 has been shown to be downregulated in various types of cancer, including breast, lung, and colorectal cancers [11,12]. Similarly, LINC01479 has been shown to be involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease [13,14].

In addition, LINC01479 has also been shown to be involved in cardiovascular diseases, such as heart failure and hypertension [15,16]. Therefore, the expression of LINC01479 could be a potential biomarker for cardiovascular diseases.

Conclusion

In conclusion, LINC01479 is a non-protein-coding RNA molecule that has been identified by bioinformatics analysis as belonging to the LINC family. It has been shown to play a crucial role in various biological processes, including cell development, tissue repair, and metabolism. The potential drug targets for LINC01479 are numerous and varied, including the inhibition of its expression, the inhibition of its function, and its role in cellular signaling pathways. Furthermore, LINC01479 has also been identified as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. Therefore, LINC01479 is a promising target for future research in drug development and personalized medicine.

Protein Name: Long Intergenic Non-protein Coding RNA 1479

The "LINC01479 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01479 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets